IBO
Impact Biomedical Inc.
$0.45
+0.00 (+0.00%)
At close · Jul 8
Market Cap
$48.70M
Shares
107,821,231
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$32K
FY2025
Net Income
-$11.84M
+52.1%
FY2025
Gross Margin
-1225%
FY2025
Operating Margin
-13381.25%
FY2025
Diluted EPS
-$0.38
+83.5%
FY2025
Operating Cash Flow
-$1.89M
+33.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | $32K | — | — | $50K | |
| — | $424K | — | — | — | |
| — | -$392K | — | — | — | |
| — | -1225% | — | — | — | |
| $283K | $340K | $278K | $1.69M | $1.23M | |
| $6000 | $24K | $633K | $65K | — | |
| $2.25M | $873K | $718K | $315K | $325K | |
| $1.15M | $1.15M | $1.12M | $1.12M | $1.11M | |
| $28.99M | — | $28.75M | $4.03M | — | |
| — | — | — | $4.03M | $3.45M | |
| -$5.56M | -$4.28M | -$28.75M | -$4.03M | -$3.4M | |
| — | -13381.25% | — | — | -6808% | |
| -$4.41M | -$3.14M | -$27.63M | -$2.91M | -$2.29M | |
| — | $793K | $1.07M | $444K | $462K | |
| — | — | — | $13K | $24K | |
| -$15.46M | -$14.45M | -$24.74M | -$4.41M | -$7.88M | |
| — | -$2.58M | $33K | — | -$621K | |
| -$12.86M | -$11.84M | -$24.71M | -$4.34M | -$7.26M | |
| — | -36993.75% | — | — | -14510% | |
| -$18K | -$32K | -$62K | -$71K | — | |
| $981K | — | — | -$4.34M | -$7.05M | |
| USD/shares | — | -$0.38 | -$2.30 | -$0.07 | -$0.10 |
| USD/shares | — | -$0.38 | -$2.30 | -$0.07 | -$0.10 |
| shares | — | 31.55M | 10.76M | 60.25M | 70.5M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 |
|---|---|
| Biotech Retail Sales | $32,000 |